The DOI matches its Crossref record; 200 of the 200 references it cites were found in a registry or an index.
In search of a pan-coronavirus vaccine: next-generation vaccine design and immune mechanisms
Open accessAbstract
Members of the coronaviridae family are endemic to human populations and have caused several epidemics and pandemics in recent history. In this review, we will discuss the feasibility of and progress toward the ultimate goal of creating a pan-coronavirus vaccine that can protect against infection and disease by all members of the coronavirus family. We will detail the unmet clinical need associated with the continued transmission of SARS-CoV-2, MERS-CoV and the four seasonal coronaviruses (HCoV-OC43, NL63, HKU1 and 229E) in humans and the potential for future zoonotic coronaviruses. We will highlight how first-generation SARS-CoV-2 vaccines and natural history studies have greatly increased our understanding of effective antiviral immunity to coronaviruses and have informed next-generation vaccine design. We will then consider the ideal properties of a pan-coronavirus vaccine and propose a blueprint for the type of immunity that may offer cross-protection. Finally, we will describe a subset of the diverse technologies and novel approaches being pursued with the goal of developing broadly or universally protective vaccines for coronaviruses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There is no effective treatment to date, 17 and despite promising advances, 18,19 no vaccine has been approved.”
From Severe acute respiratory syndrome (SARS) mathematical models and disease parameters: a systematic review (2025) · cites this paper as [18]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: SARS-CoV-2 S2–targeted vaccination elicits broadly neutralizing antibodies
Ng, K. W., Faulkner, N., Finsterbusch, K., Wu, M., Harvey, R., Hussain, S., Greco, M. T., Liu, Y., Kjær, S., Swanton, C., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn3715 · Cited by 101
RetractedA new coronavirus associated with human respiratory disease in China
Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2008-3 · Cited by 11,688
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J., & Prescott, H. C. (2020) · JAMA · doi:10.1001/jama.2020.12839 · Cited by 4,609
Long COVID: major findings, mechanisms and recommendations
Davis, H. E., McCorkell, L., Vogel, J. M., & Topol, E. J. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00846-2 · Cited by 4,153
Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19
Liao, M., Liu, Y., Yuan, J., Wen, Y., Xu, G., Zhao, J., Cheng, L., Li, J., Wang, X., Wang, F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0901-9 · Cited by 2,614
Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern
Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., Gallagher, E., Gower, C., Kall, M., Groves, N., O’Connell, A.-M., et al. (2021) · doi:10.1101/2021.12.14.21267615 · Cited by 2,420
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
Sadoff, J., Gray, G., Vandebosch, A., Cárdenas, V., Shukarev, G., Grinsztejn, B., Goepfert, P. A., Truyers, C., Fennema, H., Spiessens, B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101544 · Cited by 2,397
Global impact of the first year of COVID-19 vaccination: a mathematical modelling study
Watson, O. J., Barnsley, G., Toor, J., Hogan, A. B., Winskill, P., & Ghani, A. C. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00320-6 · Cited by 1,769
The spike protein of SARS-CoV — a target for vaccine and therapeutic development
Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2090 · Cited by 1,661
Cited by
Saha, A., Roy, S. G., Dwivedi, R., Tripathi, P., Kumar, K., Nambiar, S. M., & Pathak, R. (2025) · Vaccines · doi:10.3390/vaccines13040424 · Cited by 47
Ekanger, C. T., Kumar, N. D., Koutstaal, R. W., Zhou, F., Beukema, M., Waldock, J., Jochems, S. P., Mulder, N., van Els, C. A. C. M., Engelhardt, O. G., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1532144 · Cited by 33
Hybrid Immunity against SARS-CoV-2 Variants: A Narrative Review of the Literature
Tsagkli, P., Geropeppa, M., Papadatou, I., & Spoulou, V. I. (2024) · Vaccines · doi:10.3390/vaccines12091051 · Cited by 25
Raadsen, M. P., Dahlke, C., Fathi, A., Hardtke, S., Klüver, M., Krähling, V., Gerresheim, G. K., Mayer, L., Mykytyn, A. Z., Weskamm, L. M., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00423-7 · Cited by 24
T-Cell Immune Responses to SARS-CoV-2 Infection and Vaccination
Notarbartolo, S. (2024) · Vaccines · doi:10.3390/vaccines12101126 · Cited by 23
Metadata
- Authors
- Cankat, S., Demael, M. U., & Swadling, L.
- Affiliations
- University College London (GB)
- Corresponding author
- Swadling, L.
- Venue
- Cellular & Molecular Immunology
- Published
- 2023-12-26
- Volume
- 21
- Issue
- 2
- Pages
- 103-118
- ISSN
- 1672-7681 (ISSN-L)
- 2042-0226
- PMC
- PMC10805787
- OpenAlex
- W4390236634
- Semantic Scholar
- 644e501a110027727641db4025c3f16d8f4b80ec
- Cited by
- 84
- References
- 182
- Citations by year
- 2026: 27 · 2025: 35 · 2024: 22
- FWCI
- 3.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Cellular and Molecular Immunology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion, cc-by)
- Funders
- RCUK | Medical Research Council (MR/X502984/1, MR/W006774/1)
- RCUK | Biotechnology and Biological Sciences Research Council (BB/T008709/1)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Keywords
- pan-coronavirus vaccine, universal coronavirus vaccine, SARS-CoV-2, MERS-CoV, seasonal coronaviruses, zoonotic coronaviruses, cross-protection, antiviral immunity, vaccine design, COVID-19 vaccines
- MeSH terms
- SARS-CoV-2, COVID-19 Vaccines, Humans, Vaccination, Coronavirus OC43, Human, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: In search of a pan-coronavirus vaccine: next-generation vaccine design and immune mechanisms. https://app.cochat.ai/papers/10.1038/s41423-023-01116-8
- The paper
- Cankat, S., Demael, M. U., & Swadling, L. (2023). In search of a pan-coronavirus vaccine: next-generation vaccine design and immune mechanisms. Cellular & Molecular Immunology. https://doi.org/10.1038/s41423-023-01116-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.